These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

920 related items for PubMed ID: 18419470

  • 1. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.
    J Infect Dis; 2008 Apr 01; 197(7):950-6. PubMed ID: 18419470
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 01; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 01; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 14. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY, Khalil MK, Tischer A, Al-Jeffri MH, Al-Ghamdi YS, Bakhsh MM, Mishkas AA, Elgizouli SA.
    Saudi Med J; 2005 Oct 25; 26(10):1551-4. PubMed ID: 16228054
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P.
    Vaccine; 2009 May 05; 27(20):2701-6. PubMed ID: 19428882
    [Abstract] [Full Text] [Related]

  • 16. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.
    J Trop Pediatr; 2011 Oct 05; 57(5):347-51. PubMed ID: 21078605
    [Abstract] [Full Text] [Related]

  • 17. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.
    Pediatrics; 1986 Oct 05; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [Abstract] [Full Text] [Related]

  • 18. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S.
    Cancer; 2004 Aug 01; 101(3):635-41. PubMed ID: 15274078
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct 01; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 20. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
    Díaz-Ortega JL, Bennett JV, Castañeda D, Martinez D, de Castro JF.
    Vaccine; 2010 Oct 18; 28(44):7228-32. PubMed ID: 20800111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.